Latest news with #Ranibizumab
News18
27-05-2025
- Business
- News18
Stocks To Watch: LIC, IndiGo, Tata Motors, Dabur, DLF, Nazara Tech, And Others
Last Updated: Stocks to watch: Shares of firms like LIC, IndiGo, Tata Motors, Dabur, DLF, Nazara Tech, and others will be in focus on Tuesday's trade Stocks To Watch Stocks to Watch on May 27: Domestic equity markets kicked off the week on a strong note, gaining over half a percent amid intra-day volatility and extending Friday's rebound. On Tuesday, May 27, several stocks are expected to remain in the spotlight owing to key corporate announcements, earnings reports, and strategic developments. Key Stocks in Focus These companies are scheduled to announce their Q4FY25 results today, keeping their shares in focus during the trading session. IndiGo (InterGlobe Aviation) Co-founder Rakesh Gangwal is planning to divest up to 3.4% of his stake in the airline through a block deal, potentially raising Rs 6,831 crore. The shares will be offered at a floor price of Rs 5,175 apiece—about 4.5% below the prevailing market price. Lupin The pharmaceutical company has entered into a licensing and supply agreement with SteinCares for its biosimilar Ranibizumab, targeting Latin American markets (excluding Mexico and Argentina). The drug is used to treat retinal conditions like age-related macular degeneration and diabetic macular edema. Tata Motors According to its inaugural Tax Transparency Report, Tata Motors contributed Rs 38,892 crore in taxes and other payments globally in FY25, a marginal decline from Rs 39,344 crore in FY24. The online gaming firm posted a net profit of Rs 4 crore for Q4FY25, a substantial jump from Rs 18 lakh during the same quarter last year. The parent company of FirstCry reported a net loss of Rs 111 crore in Q4FY25, a sharp increase compared to the Rs 43 crore loss in the corresponding quarter last year. The FMCG major's board has approved the merger of Sesa Care with the company, a move aimed at consolidating its personal care business. DLF Real estate giant DLF is gearing up to launch a premium housing project in Mumbai within the next two weeks, marking a major expansion into India's financial capital. PG Electroplast The company's promoters plan to sell up to 5.62% stake via a block deal worth Rs 1,177 crore. The shares will be offered at a floor price of Rs 740 each, and a 180-day lock-in will apply to further share sales. Aurobindo Pharma The drugmaker reported consolidated revenue of Rs 8,382.1 crore for the March quarter, registering an 11% year-on-year growth and aligning closely with analyst expectations. Disclaimer:Disclaimer: The views and investment tips by experts in this report are their own and not those of the website or its management. Users are advised to check with certified experts before taking any investment decisions. First Published:
Mint
27-05-2025
- Business
- Mint
Stocks to watch: IndiGo, LIC, NMDC, Bharat Dynamics, Lupin, Tata Motors among shares in focus today
Shares of LIC, NMDC, Bharat Dynamics, Info Edge will remain in focus as companies will announce Q4 results today. Rakesh Gangwal, co-founder of InterGlobe Aviation, is planning to sell up to 3.4% of his stake in the company through a block deal, which could raise as much as ₹ 6,831 crore, according to sources. The shares will be offered at a floor price of ₹ 5,175 each—approximately 4.5% below the current market rate. The pharmaceutical company announced that it has signed a licensing and supply deal with SteinCares for its biosimilar Ranibizumab in Latin American markets, excluding Mexico and Argentina. Ranibizumab is used to treat various retinal conditions, such as age-related macular degeneration and diabetic macular edema. Online gaming firm Nazara Technology announced on Monday that it recorded a net profit of ₹ 4 crore in the fourth quarter of FY25, a significant rise from the ₹ 18 lakh it reported during the same period last year. Brainbees Solutions, the parent company of Firstcry, posted a net loss of ₹ 111 crore in the fourth quarter of FY25, a significant increase from the ₹ 43 crore loss recorded in the same quarter last year. Tata Motors contributed ₹ 38,892 crore in taxes and other payments worldwide in 2024–25, reflecting a 1% decrease from the ₹ 39,344 crore paid in FY24, as revealed in its first-ever Tax Transparency Report. Dabur's Board has given the green light for the merger of Sesa Care with the company. India's leading real estate developer is set to unveil its highly anticipated premium housing project in Mumbai within the next two weeks. The promoters of PG Electroplast plan to offload up to 5.62% of their stake through a block deal valued at ₹ 1,177 crore, setting a floor price of ₹ 740 per share. A 180-day lock-in period will apply to any additional share sales. The pharmaceutical company posted a consolidated revenue of ₹ 8,382.1 crore for the March quarter, reflecting an 11% increase compared to the same period last year, aligning closely with market expectations. Sagility B.V., the parent company of Sagility India Ltd., intends to divest up to 15.02% of its equity stake in the company via an Offer for Sale (OFS). Disclaimer: This story is for educational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified experts before making any investment decisions.
The Hindu
26-05-2025
- Business
- The Hindu
Lupin, SteinCares ink pact to roll out biosimilar for eye disease in Latin America
Drugmaker Lupin has entered into a licence and supply agreement with SteinCares for commercialisation of its biosimilar ranibizumab across Latin America, excluding Mexico and Argentina. SteinCares, which is specialty healthcare company in Latin America, will handle all regulatory filings, registrations and commercialisation of Ranibizumab in LATAM, while Lupin will be responsible for manufacturing the same, under the agreement, it said on Monday. Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). It is used in treatment of Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion, Diabetic Macular Edema, Diabetic Retinopathy and Myopic Choroidal Neovascularization, Lupin said. 'Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients,' Cyrus Karkaria, president – Biotechnology, Lupin, said in a release. Chief Strategy Officer at SteinCares Sebastian Katz said the company has consistently been the first to market products from highly regulated markets across several countries in the region. The partnership with Lupin strengthens its portfolio and reinforces SteinCares' position as a biosimilar powerhouse in Latin America.
&w=3840&q=100)
Business Standard
26-05-2025
- Business
- Business Standard
Lupin signs licensing deal with SteinCares for ranibizumab in LatAm
Lupin will manufacture biosimilar ranibizumab while SteinCares handles registration and marketing in Latin America, excluding Mexico and Argentina Anjali Singh Mumbai Pharma major Lupin has signed a licence and supply agreement with Costa Rica-based SteinCares for the commercialisation of its biosimilar ranibizumab (used to treat eye conditions) in Latin America, excluding Mexico and Argentina. As part of the agreement, SteinCares will manage regulatory filings, registrations and commercial operations in the region, while Lupin will handle manufacturing. Ranibizumab is a recombinant humanised monoclonal antibody fragment used to inhibit vascular endothelial growth factor A (VEGF-A). It is indicated for the treatment of several retinal conditions, including neovascular (wet) age-related macular degeneration, macular oedema following retinal vein occlusion, diabetic macular oedema, diabetic retinopathy and myopic choroidal neovascularisation. Cyrus Karkaria, President of Biotechnology at Lupin, said the company aims to improve access to retinal therapies in Latin America through this partnership. 'Our intent is to transform retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients,' Karkaria added. Sebastian Katz, Chief Strategy Officer at SteinCares, said the deal would enhance the company's biosimilar portfolio in the region and support cost savings for healthcare systems through access to products from highly regulated markets. 'This partnership with Lupin strengthens our portfolio and position as a biosimilar powerhouse in Latin America. We have consistently been first to market products from highly regulated markets across several countries in the region,' said Katz. Lupin is headquartered in Mumbai and operates across more than 100 markets. Its portfolio includes branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients. The company operates 15 manufacturing sites and seven R&D centres globally.
Time of India
26-05-2025
- Business
- Time of India
Lupin inks licensing deal to supply biosimilar ranibizumab in Latin America
Drug maker Lupin on Monday said it has entered into a licence and supply agreement with SteinCares for commercialisation of biosimilar ranibizumab across Latin America , excluding Mexico and Argentina. Under the terms of the agreement, SteinCares will handle all regulatory filings, registrations and commercialisation of Ranibizumab in Latin America, while Lupin will be responsible for manufacturing the same, the Mumbai-based drug maker said in a statement. Ranibizumab is a recombinant humanised IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A (VEGF-A). Its indications encompass the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), Diabetic Retinopathy (DR) and Myopic Choroidal Neovascularization (mCNV). by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free P2,000 GCash eGift UnionBank Credit Card Apply Now Undo Also Read: Lupin partners with Honeywell for usage of propellant for inhalers "Our intent is to transform the landscape of retinal care in Latin America, ensuring access to advanced therapies that improve the quality of life of patients," Lupin President Biotechnology Cyrus Karkaria said. Live Events Shares of Lupin were trading 0.32% down at ₹1,972.80 apiece on BSE.
